Bcr Abl Inhibitor Drug Market USD 8 Billion Opportunity By 2028

Global Bcr-Abl Inhibitor Market, Drug Sales & Clinical Trials Insight 2028 Report Highlights:


  • Global Bcr-Abl Inhibitor Market Opportunity > USD 8 Billion
  • Approved Bcr-Abl Inhibitor Drugs: 8 Drugs
  • Global Bcr-Abl Inhibitor Market Regional Analysis & Forecast Till 2028
  • Bcr-Abl Inhibitor Drug Market Past Sales & Future Forecast Till 2028
  • Market Analysis By First, Second & Third Generation Approved drugs
  • Bcr-Abl Inhibitor Drug Prices, Dosage & Patent Insight
  • Global Bcr-Abl Inhibitor Drug clinical Trials Insight by Indication ,Company, County & Phase


Download Report Sample: 




Chronic myeloid leukemia (CML) is a type of cancer that starts in certain blood-forming cells of the bone marrow. It most commonly occurs in the adults and very rarely it occurs in children. Chronic myeloid leukemia usually begins after age 60 and is develop slowly and treated with targeted cancer drugs such as tyrosine kinase inhibitors, chemotherapy or a bone marrow transplant. Recent advances in cancer treatments such as advent of Bcr-Abl inhibitors has drastically improved the survival rate for this type of leukemia.


Till date, a cocktail of Bcr-Abl inhibitors have been approved by the regulatory bodies which have shown encouraging clinical response in the management of CML. The advent of third generation Bcr-Abl Inhibitor, Iclusig has shown to significantly transform the paradigm of chronic myeloid leukemia treatment due to its ability to specifically target the T135I mutation and also overcoming the resistance to both second and first generation drugs. Since their entrance into the market, these drugs have shown high adoption rates which can be justified by the increasing sales of these drugs. Apart from Iclusig, Olverembatinib developed by Ascentage Pharma has gained entry into Chinese market. It is the first China-approved third-generation BCR-ABL inhibitor targeting drug-resistant  chronic myeloid leukemia (CML).


To further enhance the efficacy and overcome the drug resistance of Bcr-Abl inhibitors, several clinical trials are evaluating the role of these drugs in the management of several cancers. For instance, a recent study evaluating the combination of Bcr-Abl inhibitor imatinib (Gleevec) and the MEK inhibitor binimetinib (Mektovi) elicited encouraging responses in patients with treatment-naïve advanced gastrointestinal stromal tumors (GIST). The novel combination has shown to significantly improve the overall survival rate in comparison to monotherapy. In addition, there were no reported treatment related adverse events during the trial.


In addition to this, the patent of several Bcr-Abl inhibitors are going to expire in different regions during the forecast period. The patent expiration of the drugs opens opportunities for the development of generic drugs which are cost-efficient and helps to considerably reduce the financial toxicity on patients. Moreover, it increases the competition among pharmaceutical companies to increase their revenue in market. Currently, generic version of Gleevec is present in market which has shown high adoption rates in the market which can be justified by the significant decline in the sales of branded drugs. The availability of cost effective generic versions of Bcr-Abl inhibitors will increase their accessibility, thus propelling the growth of market in forthcoming years.


As per our report findings, the global Bcr-Abl inhibitor market is expected to surpass US$ 8 Billion by 2028. The market is growing with high CAGR rates owing to The chronic myeloid leukemia treatment market is growing due to the increase in the incidences and prevalence of chronic myeloid leukemia, growing awareness towards CML, and escalation in the research and development activities. Further, large numbers of ongoing clinical trials are also evaluating the role of these drugs in the management of several other cancers including lung cancer, gastrointestinal stromal cancers, which will also drive the growth of market. In addition, the robust clinical pipeline of drugs which are expected to gain approval during the forecast period will also have a positive impact on the growth of market.


The report provides an in-depth analysis on Bcr-Abl inhibitors market with description of market sizing and growth. The analysis includes market by value, by drug and by region. Furthermore, the report also provides detailed drug and regional analysis. Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and would be driving the growth of the industry. The key players in global Bcr-Abl inhibitors market are Ascentage Pharma, AstraZeneca, Merck, Fusion Pharmaceuticals, Takeda Pharmaceuticals, Novartis, amongst others.


For More Information Related To Report Contact:


Neeraj Chawla

Research Head

Kuick Research






Back to news